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Abstract
Background: Previously we identified a DNA damage response–deficient (DDRD) molecular subtype within breast cancer.
A 44-gene assay identifying this subtype was validated as predicting benefit from DNA-damaging chemotherapy. This sub-
type was defined by interferon signaling. In this study, we address the mechanism of this immune response and its possible
clinical significance.
Methods: We used immunohistochemistry (IHC) to characterize immune infiltration in 184 breast cancer samples, of which
65 were within the DDRD subtype. Isogenic cell lines, which represent DDRD-positive and -negative, were used to study the
effects of chemokine release on peripheral blood mononuclear cell (PBMC) migration and the mechanism of immune signal-
ing activation. Finally, we studied the association between the DDRD subtype and expression of the immune-checkpoint pro-
tein PD-L1 as detected by IHC. All statistical tests were two-sided.
Results: We found that DDRD breast tumors were associated with CD4þ and CD8þ lymphocytic infiltration (Fisher’s exact
test P < .001) and that DDRD cells expressed the chemokines CXCL10 and CCL5 3.5- to 11.9-fold more than DNA damage
response–proficient cells (P < .01). Conditioned medium from DDRD cells statistically significantly attracted PBMCs when
compared with medium from DNA damage response–proficient cells (P < .05), and this was dependent on CXCL10 and CCL5.
DDRD cells demonstrated increased cytosolic DNA and constitutive activation of the viral response cGAS/STING/TBK1/IRF3
pathway. Importantly, this pathway was activated in a cell cycle–specific manner. Finally, we demonstrated that S-phase
DNA damage activated expression of PD-L1 in a STING-dependent manner.
Conclusions: We propose a novel mechanism of immune infiltration in DDRD tumors, independent of neoantigen
production. Activation of this pathway and associated PD-L1 expression may explain the paradoxical lack of T-cell-mediated
cytotoxicity observed in DDRD tumors. We provide a rationale for exploration of DDRD in the stratification of patients for
immune checkpoint–based therapies.
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The presence of an immune response is recognized to be a prog-
nostic factor in breast cancer (1,2). The underlying mechanisms
driving this response are unclear. It has been proposed that
DNA released from apoptotic cells or tumor neoantigen produc-
tion may be responsible for this immune response; however,
these mechanisms do not explain the absence of response in
other tumors (3). Previously (4) we used unsupervised hierarchi-
cal clustering of gene expression data to identify a DNA damage
response–deficient (DDRD) molecular subtype in breast cancer
and demonstrated that this represented loss of the S-phase-
specific DNA damage response mechanism, the Fanconi
Anemia (FA)/BRCA pathway. Based on this, we developed a 44-
gene expression assay that could prospectively identify this
group of tumors and demonstrated that it could predict benefit
from DNA-damaging chemotherapy, presumably because of
inherent defects in DNA repair capacity (4). Importantly, upre-
gulation of interferon-related genes was observed in the DDRD
molecular subtype, and DDRD assay–positive tumors were asso-
ciated with lymphocytic infiltration. However, the key pathways
driving this biology were unknown. In this current study, we ex-
plore the activation of immune genes identified in the DDRD
molecular subtype.
Methods
Further details of methods can be found in Supplementary
Materials (available online).
Cell Lines
MDA-MB-436-EV and MDA-MB-436 -BRCA1 were a kind gift from
Ms. Paula Haddock (Queens University Belfast, UK) and were gen-
erated by transfecting the BRCA1-mutant MDA-MB-436 cells with
either empty Rc/CMV or Rc/CMV-BRCA1, followed by selection in
300 lg/mL G418 (Roche, Basel, Switzerland). HCC1937-EV and
HCC1937-BRCA1 have been described previously (5). These iso-
genic cell lines were used to model the immune effects of BRCA1
deficiency. Hela cells (ATCC, Manassas, VA) were used to investi-
gate the effects of exogenous DNA damage.
Immunohistochemistry
Immunohistochemistry (IHC) was performed in the Northern
Ireland Molecular Pathology Laboratory using the Ventana
Discovery-XT Automated Stainer. A tissue microarray of a previ-
ously described cohort (4) of 184 N0-N1 estrogen receptor (ER)–
positive and ER-negative formalin-fixed, paraffin-embedded
(FFPE) breast tumor samples (ethics number NIB12-0043) was
scored in triplicate. CD4 (4B12, M7310, Dako, Ely, UK) and CD8
antibodies (C8/144B, M7103, Dako) were used at 1:50, PD-L1 anti-
body (SP142, Roche) at 1:40 with an amplification step using
OptiView Amplification Kit (Roche). A semiquantitative scoring
system was employed for CD4þ and CD8þ characterization. A
score of 3 indicates strong CD4þ or CD8þ expression, 2 moderate
expression, 1 low or weak expression, 0 absence. Scores were de-
termined by two independent observers. For PD-L1, previously
published cutoffs of 1% or greater and 5% or greater were used (6).
Migration Assay
Peripheral blood mononuclear cells (PBMCs) were obtained from
buffy coats of 12 healthy donors, with written informed consent
obtained and ethical approval granted from the Northern
Ireland Blood Transfusion Service. Using Corning Transwell
polycarbonate membrane 5 lm inserts (Sigma Aldrich, St Louis,
MO), PBMCs were resuspended in Optimem 0.5% BSA, and 5x105
PBMCs placed in the top chamber. In the bottom chamber, con-
ditioned media (from indicated cell lines 6 transfected knock-
downs) was placed. Media was changed to optimem on day 1,
and collected on day 3. For CXCR3 inhibition, 100 nM SCH546738
(7), synthesized in-house, was added to the PBMCs. After four
hours, the migration of PBMCs to the bottom chamber was mea-
sured using a Cell Titre Glo assay (Promega, Madison, WI) with a
standard curve to calculate cell number.
Immunofluorescence
MDA-MB-436-EV, HCC1937-EV, and their BRCA1-complemented
isogenic pairs were seeded on coverslips. HeLa cells were
treated with IC50 doses of cisplatin, hydroxyurea and paclitaxel,
and DMSO control for 48 hours. Cells were washed with phos-
phate-buffered saline prior to the addition of fresh medium
containing PicoGreen DNA stain (4 mg/mL). Following incubation
at 37 C for two hours, fixation was performed with 4% parafor-
maldehyde. Coverslips were mounted using Prolong Gold with
DAPI (Thermo Fisher, Renfrew, PA). Cytosolic dsDNA staining
was assessed by selection of random fields of view using a
Nikon Eclipse Ti Fluorescent Microscope.
Statistical Analysis
Each experiment was carried out at least in triplicate. To deter-
mine statistical significance, the unpaired, two-tailed Student’s
t test was calculated using the t test calculator available on
GraphPad Prism 5.0 software. Fisher’s exact test was calculated
using the online calculator available at http://in-silico.net/tools/
statistics/fisher_exact_test. Statistical significance is defined as
a P value of less than .05. All statistical tests were two-sided.
Results
Analysis of CD41 and CD81 T-Lymphocytes in DDRD
Assay–Positive and –Negative Tumors
As we had observed upregulation of interferon-related genes
including T-cell-specific ligands in the epithelial component of
tumors classified within the DDRD molecular subtype
(Supplementary Table 1, available online) (4), we asked if these
were associated with a T-cell immune response. The presence of
intratumoral and stromal CD4þ and CD8þ T-lymphocytes were
assessed by IHC using a semiquantitative score in a previously
described cohort of 184 N0-N1 ER-positive and ER-negative
breast tumor samples, scored as DDRD molecular subtype–
positive or –negative using the DDRD assay according to the cut-
off value defined in Mulligan et al. (4). Patient characteristics and
histopathological factors are given in Supplementary Table 2
(available online).
A statistically significant association of intratumoral and
stromal CD4þ and CD8þ T-lymphocytes with DDRD assay–posi-
tive tumors was identified (P < .001) (Table 1). In the DDRD-
positive cohort (n ¼ 65), 53.9% of cores scored as having moder-
ate/high intratumoral CD8þ lymphocytic infiltrate, compared
with 16.2% of DDRD assay–negative tumors (n ¼ 117). Similarly,
a strong association of CD4þ intratumoral lymphocytic infiltra-
tion was identified with DDRD assay–positive tumors compared
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Figure 1. Immune gene expression in FA/BRCA DNA repair pathway loss. A) Immunohistochemistry (IHC) images (x40) showing absence of CD8þ and CD4þ lymphocytes
in DDRD assay–negative tumors, and both intratumoral and stromal CD8þ and CD4þ lymphocytes in DDRD assay–positive breast tumors. Scale bar represents 100 mm. B)
Quantitative polymerase chain reaction (qPCR) measurement of CCL5 and CXCL10 chemokine mRNA expression following knockdown of BRCA1, BRCA2, and FANCD2 in
HeLa cells using two independent siRNAs (a and b) compared with control siRNA (AS). GAPDH siRNA has also been used as a negative control. C) qPCR measurement (left
panel) of CCL5 and CXCL10 chemokine mRNA expression in MDA-MB-436-EV and HCC1937-EV BRCA1-mutant cell lines compared with BRCA1-corrected MDA-MB-436
and HCC1937-BRCA1 cell lines. CXCL10 and CCL5 quantification by enzyme-linked immunosorbent assay (ELISA) of media collected from MDA-MB-436 BRCA1 and empty
vector counterparts (EV) are shown in the right panel. D) Migration of activated peripheral blood mononuclear cells (PBMCs) toward conditioned media from MDA-MB-
436-EV compared with MDA-MB-436-BRCA1 using a Boyden Invasion Chamber Assay. E) Migration of activated PBMCs toward conditioned media from MDA-MB-436-EV
cells treated with CXCL10 and CCL5 siRNA compared with nontargeting siRNA control (AS) using a Boyden invasion chamber assay. See also Supplementary Figure 1, C
and D (available online). F) qPCR measurement of CXCL10 and CCL5 mRNA in MDA-MB-436-EV and HCC1937-EV cells arrested in S-phase using double-thymidine block (2.
5 mM) (top left panel) and M-phase using nocodazole (100 ng/mL) (bottom left panel). Cell cycle analysis following double-thymidine treatment as compared with phos-
phate-buffered saline (PBS) control is shown in the top right panel, and nocodazole-treated cells as compared with DMSO control in the bottom right panel. G) qPCR
measurement of CXCL10 and CCL5 mRNA expression in HeLa (left panel), MDA-MB-436-EV (center panel), and HCC1937-EV (right panel) cells 24 hours following treatment
with cisplatin, HU, or paclitaxel at IC50 concentration for each cell line, and the data was normalized to PUM1 expression. Data are represented as mean 6 SD, and P val-
ues were calculated using the unpaired, two-tailed Student’s t test. *P < .05, †P < .01, ‡P < .001. DDRD ¼ DNA damage response–deficient; PBMC ¼ peripheral blood mono-
nuclear cell; PBS ¼ phosphate-buffered saline.
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with DDRD assay–negative (24.6% vs 3.4% scoring moderate/
high). In assessment of the stromal component of the tumor,
89.3% of DDRD assay–positive tumors were associated with
moderate/high CD8þ stromal expression, compared with 56.4%
of DDRD assay–negative, and 80.0% of DDRD assay–positive
tumors were associated with stromal CD4þ expression vs 32.8%
DDRD-negative (Table 1, Figure 1A). In DDRD assay–positive
samples, a statistically significant association between CD4þ
and CD8þ lymphocytes in the intratumoral and stromal com-
partments was identified (P < .001).
Assessment of Chemokine Production in the Context of
DNA Damage Response Deficiency
CXCL10 is the most discriminative gene by weight in the DDRD
assay (4) and has previously been reported as a prognostic factor
in breast cancer (4,8). CCL5 was identified as the top differen-
tially expressed chemokine in DDRD assay–positive ER-negative
tumors compared with DDRD-negative ER-negative tumors
(Supplementary Table 3, available online). As the CXCL10/
CXCR3 axis has been reported as key for the chemotaxis
of CD4þ and CD8þ T-lymphocytes (9), and CXCL10 and CCL5
overexpression is associated with the presence of CD8þ lym-
phocytes in melanoma, gastric, and colorectal cancers (10–12),
we investigated the link between the DDRD molecular subtype
and chemokine expression. We used siRNA to knock down the
expression of the FA-BRCA pathway genes BRCA1, BRCA2, and
FANCD2 in HeLa cells and observed statistically significant
upregulation of CXCL10 and CCL5 (P < .05) (Figure 1B;
Supplementary Figure 1A, available online). Next we assessed
CXCL10 and CCL5 expression in BRCA1-mutant DNA damage
response–deficient cell lines HCC1937 and MDA-MB-436, stably
transfected with either an empty expression vector (EV) or
the vector containing wild-type BRCA1 cDNA (BRCA1)
(Supplementary Figure 1B, available online). Using these iso-
genic models, we observed statistically significant repression of
CXCL10 and CCL5 in the BRCA1-complemented lines compared
with their DDRD counterparts at the mRNA level and protein
level from conditioned media (P < .05) (Figure 1C). Importantly,
because the phenotype was observed in cell lines, this indicated
that the observed production of chemokines in tumors within
the DDRD molecular subtype could arise from the epithelial
component.
To test if the upregulation of CXCL10 and CCL5 in cancer
cells could result in lymphocytic infiltration, migration of pe-
ripheral blood mononuclear cells into conditioned media from
MDA-MB-436-EV and BRCA1-corrected cells was assessed. This
demonstrated a statistically significant increase in migration
into media conditioned by MDA-MB-436-EV cells compared
with their BRCA1-corrected counterparts (P ¼ .02) (Figure 1D).
Additionally, siRNA-mediated knockdown of CXCL10 and CCL5
reduced PBMC migration, indicating their importance for lym-
phocytic infiltration (P < .05) (Figure 1E; Supplementary Figure
1C, available online). Using the CXCR3 inhibitor SCH546738 (tar-
geting the CXCL10 receptor), we also observed reduced PBMC
migration (P < .001) (Supplementary Figure 1D, available online).
Together these data suggest that DNA damage response de-
ficiency in breast cancer cells can result in the production of
chemokines that stimulate lymphocytic migration.
DNA Damage–Associated Chemokine Expression in
Relation to Phase of the Cell Cycle
As the DDRD molecular subtype in breast cancer was previously
reported to be associated with loss of the FA/BRCA pathway (4),
an S-phase-specific DNA repair mechanism, and endogenous
DNA damage would therefore be expected to be maximal in the
S-phase, we asked if chemokine release would be related to the
phase of the cell cycle. MDA-MB-436-EV and HCC1937-EV cells
were synchronized at S-phase or M-phase of the cell cycle.
Quantitative polymerase chain reaction (qPCR) analysis of
S-phase cells showed an increase in CXCL10 and CCL5 expres-
sion, whereas M-phase cells predominantly showed a reduction
in chemokine expression (Figure 1F). As the type of sporadic
DNA damage that would be expected following the loss of the
FA/BRCA pathway is predominantly S-phase in nature, we fur-
ther investigated the role of cell cycle–specific DNA damage. We
assessed the effect of cisplatin or hydroxyurea on CXCL10 and
CCL5 expression in a DNA repair–competent cell (Hela) using
predetermined IC50 doses (Supplementary Figure 1E, available
online). The microtubule stabilizer paclitaxel was used as an
M-phase control. mRNA expression of CXCL10 and CCL5 was
statistically significantly upregulated following treatment with
cisplatin and HU, but not with paclitaxel (P < .01) (Figure 1G).
Together these data support an S-phase-specific signal for acti-
vation of the immune response to DNA damage. A similar in-
duction of cytokines in response to S-phase-specific DNA
damage was noted in DDRD-positive HCC1937-EV and MDA-
MB-436-EV cells vs their corrected isogenic pair (Figure 1G;
Supplementary Figure 1G, available online).
Table 1. CD8þ and CD4þ intratumoral and stromal lymphocytic in-
filtrate assessed by IHC in DDRD-positive and DDRD-negative breast
tumors
Score
DDRD positive,
No. (%)
DDRD negative,
No. (%) P*
Intratumoral
CD8þ 65 (100) 117 (100) <.001
3 6 (9.2) 0 (0.0)
2 29 (44.6) 19 (16.2)
1 25 (38.5) 68 (58.1)
0 5 (7.7) 30 (25.6)
CD4þ 65 (100) 119 (100) <.001
3 3 (4.6) 1 (0.8)
2 13 (20.0) 3 (2.5)
1 43 (66.2) 75 (63.0)
0 6 (9.2) 40 (33.6)
Stromal
CD8þ 65 (100) 117 (100) <.001
3 20 (30.8) 8 (6.8)
2 38 (58.5) 58 (49.6)
1 7 (10.8) 44 (37.6)
0 0 (0.0) 7 (6.0)
CD4þ 65 (100) 119 (100) <.001
3 21 (32.3) 7 (5.9)
2 31 (47.7) 32 (26.9)
1 13 (20.0) 66 (55.5)
0 0 (0.0) 14 (11.8)
* P values were calculated using a two-sided Fisher’s exact test. DDRD ¼ DNA
damage response–deficient; IHC ¼ immunohistochemistry.
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Chemokine Expression and Relationship to DNA
Damage Response Kinases
Next we wanted to investigate whether ATM, ATR, or DNAPK,
the three main kinases activated in response to DNA damage,
were necessary for the chemokine upregulation in DDRD cells.
Activation of ATM has previously been reported to result in the
upregulation of immune genes, suggesting that this kinase may
be required for chemokine production in DNA damage response
deficiency (13). We therefore treated DDRD cells (MDA-MB-436-
EV and HCC1937-EV) with small molecule inhibitors of ATM,
ATR, and DNA-PK and observed no reduction in CXCL10 and
CCL5 expression (Figure 2A; Supplementary Figure 2A, available
online). Together these data indicate that these classic DNA
damage response kinases are not required for the chemokine
response observed in DDRD cells.
Activation of the STING/TBK1/IRF3 Pathway in DDRD
Cancer Cells
To identify potential transcription factors that could activate
the immune response observed in DDRD cells, we performed in
silico analysis of differentially expressed genes from DDRD as-
say–positive ER-negative tumors compared with DDRD assay–
negative using Toppfun analysis software (https://toppgene.
cchmc.org/enrichment.jspp). Interferon regulatory factors (IRFs)
were identified as the predominant transcription factors
Figure 2. The role of STING, TBK1, and IRF3 in DNA damage–dependent chemokine expression. A) quantitative polymerase chain (qPCR) measurement of CXCL10 and
CCL5 mRNA extracted from MDA-MB-436-EV and HCC1937-EV cells treated with small molecule inhibitors to ATM (1 mm Ku60019), ATR (5 mm ETP46464), and DNA-PK
(5 mm Nu7441) for 24 hours. B) Immunoblots of immunoprecipitate from whole cell lysate from MDA-MB-436-EV, MDA-MB-436- BRCA1, HCC1937-EV, and HCC1937-
BRCA1 cells for phosphorylation of IRF3 (ser396) and TBK1 (ser172) are shown. IRF3, TBK1, and Actin from whole cell lysates are also shown. C) qPCR measurement of
CXCL10 and CCL5 mRNA 72 hours following knockdown of STING using two independent siRNAs (a and b) in MDA-MB-436-EV and HCC1937-EV cells normalized to a
nontargeting siRNA control (AS). D) qPCR measurement of CXCL10 and CCL5 mRNA 72 hours following knockdown of TBK1 or IRF3 using two independent siRNAs (a
and b) in MDA-MB-436-EV (top panel) and HCC1937-EV cells (bottom panel) normalized to a nontargeting siRNA control (AS), and GAPDH siRNA was used as a negative
control. All data are representative of mean 6 SD, and P values were calculated using the unpaired, two-tailed Student’s t test. *P < .05, †P < .01, ‡P < .001.
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Figure 3. Analysis of cytosolic DNA in DNA damage response deficiency. A) Immunoblot for Histone H3 in the cytosolic fraction of DNA damage repair–deficient cell
lines (MDA-MB-436-EV and HCC1937-EV) compared with isogenic BRCA1–corrected cells (MDA-MB-436-BRCA1 and HCC1937-BRCA1). Actin is included as a loading con-
trol. Nuclear Lamin B1 shows degree of fractionation achieved. Densitometry has been performed on Histone H3 expression in Supplementary Figure 3B (available on-
line). B) PicoGreen staining of MDA-MB-436 and HCC1937 BRCA1-complemented and empty vector counterparts. Scale bar represents 10 mm. C) Immunoblot for
Histone H3 in the cytosolic of HeLa cells treated with IC50 dose cisplatin (1.46 mM) and hydroxyurea (326 mM) compared with a DMSO control. Actin and Lamin B1 are in-
cluded as loading controls. Densitometry has been performed on Histone H3 expression in Supplementary Figure 3B (available online). D) Immunoblot for cGAS using
Histone H3 immunoprecipitate from the cytoplasmic fraction of MDA-MB-436-EV and HCC1937-EV cells. Total cGAS, Histone H3 input, and Actin loading controls are
shown. E) Immunoblot for cGAS using Histone H3 immunoprecipitate from the cytoplasmic fraction of HeLa cells treated with cisplatin and HU compared with DMSO
control. Total cGAS, Histone H3 input, and Actin loading controls are shown. F) Quantitative polymerase chain reaction (qPCR) measurement of CXCL10 and CCL5
mRNA expression in MDA-MB-436-EV and HCC1937-EV cells using two independent siRNAs targeting cGAS (a and b), compared with nontargeting siRNA control (AS).
G) qPCR measurement of CXCL10 and CCL5 mRNA 48 hours after IC50 dose cisplatin (1.46 mM) (left panel) and hydroxyurea (326 mM) (right panel treatment in HeLa cells).
cGAS expression was knocked down 24 hours prior to drug treatment using two independent siRNAs targeting cGAS (a and b). A nontargeting siRNA control (AS) is in-
cluded. All data are representative of mean 6 SD, and P values were calculated using the unpaired, two-tailed Student’s t test. *P < .05, †P < .01, ‡P < .001.
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binding the promoter regions of genes differentially expressed
between the DDRD assay–positive and –negative tumors
(Supplementary Figure 2B, available online). Both CXCL10 and
CCL5 had an IRF3 binding motif within the promoter region.
IRF3 is activated in response to DNA-damaging agents (14), is a
major effector of the STING/TBK1 signaling pathway, and has
been reported to regulate expression of CXCL10 (15). STING-defi-
cient mice do not demonstrate CD8þ expansion in response to
stimulation with exogenous DNA and lack an inflammatory in-
filtrate following treatment with the powerful carcinogen DMBA
(16,17). We therefore hypothesized that the STING/TBK1/IRF3
pathway is active in DDRD cancer cells. Supporting this, we ob-
served constitutive phosphorylation (activation) of IRF3 from
whole cell lysates of BRCA1-mutant MDA-MB-436-EV and
HCC1937-EV cells, compared with their BRCA1-corrected iso-
genic lines (Figure 2B). Similarly, TBK1 was constitutively phos-
phorylated in the DDRD MDA-MB-436-EV and HCC1937-EV cell
lines compared with the isogenic corrected cell lines (Figure 2B).
siRNA-mediated knockdown of STING, TBK1, and IRF3 resulted
in reduced expression of chemokines in BRCA1-mutant cells, in-
dicating that this pathway is required for chemokine production
in DDRD cells (Figure 2, C and D).
Identification of Cytosolic DNA in the
Presence of DNA Damage
The cytosolic DNA sensor cGAS has been described as the most
potent activator of the STING pathway (18). We therefore asked if
cytosolic DNA detected by cGAS was associated with the ob-
served immune response in DDRD cells. Firstly, we analyzed
cytosolic fractions of MDA-MB-436-EV and -BRCA1, and
HCC1937-EV and -BRCA1 cells, for the presence of Histone H3 (a
marker of DNA) and found Histone H3 cytosolic protein expres-
sion was increased in the DDRD BRCA1-mutant cells (Figure 3A;
confirmed with densitometry in Supplementary Figure 3B, avail-
able online). To confirm the presence of cytosolic DNA in DDRD
cells, the HCC1937-EV and MDA-MB-436-EV cells and their
BRCA1-corrected isogenic pairs were stained with PicoGreen.
This confirmed increased DNA within the BRCA1-deficient cells
compared with the corrected cell lines (Figure 3A). We confirmed
that the increased expression of Histone H3 was specific to S-
phase DNA damage by treating HeLa cells with cisplatin and HU
(Figure 3B). Furthermore, PicoGreen staining of HeLa cells treated
with IC50 doses of cisplatin and HU revealed increased cytosolic
DNA under confocal microscopy (Supplementary Figure 3A,
available online). This increase in cytosolic DNA was not ob-
served in response to treatment with paclitaxel.
Next we asked if cGAS was bound to DNA following endoge-
nous or exogenous DNA damage. We demonstrated that cGAS
and Histone H3 were bound in the cytosolic fraction of the
DDRD-positive cells MDA-MB-436-EV and HCC1937-EV (Figure
3C). To confirm the relationship to S-phase-specific DNA dam-
age, HeLa cells were treated with IC50 doses of cisplatin and HU,
cGAS was again bound to Histone H3, and this interaction was
not observed in the DMSO-treated control (Figure 3D). siRNA-
mediated knockdown of cGAS resulted in statistically signifi-
cant reduction in CCL5 and CXCL10 expression in BRCA1-
mutant cells (P < .01) (Figure 3E). Importantly, knockdown of
STING or cGAS reduced upregulation of chemokine expression
in response to cisplatin or HU, reinforcing the importance of
this pathway in signaling S-phase-specific DNA damage (Figure
3F). These data support the requirement of cGAS for the expres-
sion of chemokines in response to DNA damage.
Analysis of PD-L1 Expression in the Context
of S-Phase DNA Damage
As PD-L1 is one of the genes assessed in the DDRD assay and its
upregulated expression is associated with the DDRD assay–
positive molecular subtype, we hypothesized that increased ex-
pression of this immune checkpoint gene may provide an ex-
planation for the lack of immune-mediated cytotoxicity
observed in cancers within the DDRD molecular subtype despite
lymphocytic infiltration (5). Consistent with this hypothesis,
siRNA knockdown of BRCA1 in HeLa cells upregulated PD-L1 ex-
pression as measured by qPCR (Figure 4A) and Immunoblotting
(Figure 4B).
To confirm the relationship between PD-L1 expression and
S-phase-specific DNA damage, HeLa, HCC1937-EV, and MDA-
MB-436-EV cell lines were exposed to cisplatin and hydroxy-
urea. Enhanced expression of PD-L1 at mRNA and protein level
was observed in response to S-phase DNA damage but not pacli-
taxel (Figure 4, C and D). These data are consistent with PD-L1
induction being predominantly related to S-phase-specific DNA
damage. Additionally, siRNA knockdown of STING abrogated
upregulation of PD-L1 in response to cisplatin, indicating the re-
quirement of this cytosolic DNA-sensing pathway for immune
checkpointing following DNA damage (Figure 4E).
Analysis of Expression of PD-L1 in Breast Tumors
Within the DDRDMolecular Subtype
To determine if PD-L1 expression was observed in breast can-
cers within the DDRD molecular subtype, we performed IHC
analysis of the cohort of breast tumors previously scored for
CD4þ and CD8þ lymphocytic infiltration. Previously published
cut-offs of 1% or greater and 5% or greater were used to define
PD-L1 positivity (Figure 4F) (6). A statistically significant associa-
tion between PD-L1 expression and a positive score for the
DDRD assay was observed at both of the predefined cut-offs (P <
.001). Interestingly, both tumor epithelial cell PD-L1 positivity
and infiltrating immune cell PD-L1 expression were statistically
significantly associated with DDRD assay positivity (Table 2,
Figure 4G), indicating that DDRD epithelial cells are not only as-
sociated with PD-L1 expression but may also induce PD-L1 ex-
pression in infiltrating lymphocytes.
Discussion
The DDRD molecular subtype represents tumors that have loss
of function of the FA/BRCA pathway, an important response
mechanism to stalled DNA replication in the S-phase of the cell
cycle. Our new data suggest that in the absence of a functional
FA/BRCA pathway or as a result of exogenous DNA damage,
there is a mechanism through which an accumulation of cyto-
solic DNA activates the STING/TBK1/IRF3 innate immune
response.
Genomically unstable breast cancers such as BRCA1-mutant
are characterized by lymphocytic infiltration (19). Previous stud-
ies have suggested that genomic instability may activate im-
mune signaling through the production of neoantigens (3). Our
model proposes cytosolic DNA in the epithelial component of
the cancer as an important immune stimulus that does not re-
quire recognition of abnormal proteins. Although it is unclear
why S-phase DNA damage should result in cytosolic DNA, we
hypothesize that this may be a byproduct of re-establishing
DNA replication. There is some evidence that the cell may
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Figure 4. PD-L1 expression in DNA damage response deficiency. A) Quantitative polymerase chain reaction (qPCR) measurement of PD-L1 expression in HeLa cells us-
ing two independent siRNAs targeting BRCA1 (a and b), compared with nontargeting siRNA control (AS). B) Immunoblot of PD-L1 and BRCA1 protein expression in HeLa
cells following two independent siRNAs targeting BRCA1 (a and b). Actin is shown as a loading control. C) qPCR measurement of PD-L1 mRNA expression in HeLa,
MDA-MB-436-EV, and HCC1937-EV cells 24 hours following treatment with cisplatin, HU, and paclitaxel at the IC50 dose appropriate for each cell line. All data are repre-
sentative of mean 6 SD, and P values were calculated using the unpaired, two-tailed Student’s t test. *P < .05, †P < .01, ‡P < .001. D) Immunoblot for PD-L1 protein ex-
pression in HeLa, MDA-MB-436-EV, and HCC1937-EV cells 24 hours following treatment with IC50 doses of cisplatin, HU, and paclitaxel. Actin is included as a loading
control. E) Immunoblot for PD-L1 in HeLa cells after siRNA-mediated knockdown of STING using two independent siRNAs (a and b) from one to 12 hours following cis-
platin treatment (10 mM). A nontargeting siRNA control (AS) is included. Actin is included as a loading control. F) Immunohistochemistry (IHC) images (x20) represent-
ing immunostaining for PD-L1 in no staining (upper panel), epithelial staining (middle panel), and immune staining (lower panel). Scale bar represents 100 mm. G)
Boxplot graph showing relationship between DDRD assay score and PD-L1 expression as assessed by IHC at1% (upper panel) and 5% (lower panel) cut-offs. DDRD ¼
DNA damage response–deficient.
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actively export DNA fragments from the nucleus, possibly to
prevent misincorporation into genomic DNA (20). Normally
cytosolic DNA is processed by cytoplasmic DNase II; however, it
may be that this mechanism is overwhelmed by a failure to re-
spond to endogenous DNA damage or following exogenous
DNA damage, thereby triggering the cGAS-mediated innate im-
mune response. Indeed, similar activation of the STING path-
way in response to accumulation of cytosolic DNA has been
observed in systemic lupus erythematosus (21).
Our DDRD gene assay contains two immune checkpointing
genes that represent therapeutic targets, PD-L1 and IDO1 (4).
Inhibition of the PD-1/PD-L1 axis has resulted in dramatic re-
sponses in a subset of patients with advanced solid tumors in-
cluding melanoma and non–small cell lung cancer (22).
Importantly, our observation that DDRD-positive tumors associ-
ate with PD-L1 expression provides a rationale for exploration
of immune checkpoint treatments in this molecular subtype. In
support of this approach is the recent report for the utility of
PD-1 inhibitors in mismatch repair–deficient colorectal cancer
(23). Mismatch repair proteins have been reported to have a role
in the response to S-phase replication fork stalling (24), which
our study suggests should activate the cGAS/STING pathway,
upregulating PD-L1 expression. Whereas the ligands CXCL10
and CCL5 are known to be direct targets of IRF3, PD-L1 is not
known to have an IRF3-binding region in the promoter. Other
groups, however, have reported a dependence on STING and
TBK1 for PD-L1 upregulation consistent with our findings
(25,26). Therefore, there may be an indirect mechanism of regu-
lation, possibly through targets of IRF3 such as interferon beta
(27). Interestingly, where we observed tumor cell expression of
PD-L1, PD-L1 was also expressed on infiltrating immune cells,
suggesting the cytokine release from tumor cells may also acti-
vate PD-L1 expression in the tumor microenvironment.
The S-phase-specific nature of the immune signal also raises
a potentially important issue around combination therapies with
immune checkpoint agents. Interestingly, direct activation of the
STING pathway using synthetic cyclic dinucleotide molecules
has been reported to enhance responses to PD-1 antibodies,
which is in keeping with our data (28). Another logical combina-
tion may be an S-phase-specific DNA-damaging agent such as
cisplatin along with a PD-1/PD-L1 antibody. Antimicrotubule
agents, however, may antagonize PD-1/PD-L1 antibodies by caus-
ing cell cycle arrest in the mitotic phase of the cell cycle, thereby
preventing the STING-mediated immune response.
An important limitation of this study is the absence of im-
mune infiltration in tissue culture models, which means we
were unable to study the effects of immune checkpointing on
tumor cytotoxicity. We therefore intend to extend this work
into syngeneic animal model systems to test the sensitivity
of tumors with S-phase-specific DNA damage to PD-L1
inhibition.
In summary, we have identified a mechanism of immune re-
sponse in breast tumors deficient in DNA repair. Activation of
the innate immune STING-mediated pathway is responsible for
chemokine production in response to DNA damage in vitro, re-
sulting in an inflammatory microenvironment in DDRD breast
tumors. Expression of PD-L1 is associated with tumors deficient
in DNA damage repair, and we provide a rationale for investi-
gating the role of immune treatments in the context of endoge-
nous or exogenous S-phase DNA damage.
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Table 2. PD-L1 expression assessed by IHC in DDRD-positive and
DDRD-negative breast tumors
PD-L1 expression
DDRD
positive,
No. (%)
DDRD
negative,
No. (%) P*
1% score
Tumor 64 (100) 111 (100) <.001
PD-L1  1% 29 (45.3) 5 (4.5)
PD-L1 < 1% 35 (54.7) 106 (95.5)
Immune cells 64 (100) 111 (100) <.001
PD-L1  1% 48 (75.0) 9 (8.1)
PD-L1 < 1% 16 (25.0) 102 (91.9)
Tumor/immune cells 64 (100) 111 (100) <.001
PD-L1  1% 48 (75.0) 9 (8.1)
PD-L1 < 1% 16 (25.0) 102 (91.9)
5% score
Tumor 64 (100) 111 (100) <.001
PD-L1  5% 13 (20.3) 4 (3.6)
PD-L1 < 5% 51 (79.7) 107 (96.4)
Immune cells 64 (100) 111 (100) <.001
PD-L1  5% 25 (39.1) 3 (2.7)
PD-L1 < 5% 39 (79.7) 108 (97.3)
Tumor/immune cells 64 (100) 111 (100) <.001
PD-L1  5% 28 (43.8) 6 (5.4)
PD-L1 < 5% 36 (56.3) 105 (94.6)
* P values were calculated using a two-sided Fisher’s exact test. DDRD ¼ DNA
damage response–deficient; IHC ¼ immunohistochemistry.
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